SeekingAlpha · Sep 25, 2026
CD
NASDAQ · CDNA
CareDx, Inc
Healthcare · Medical - Diagnostics & Research
$63.79
Down-$6.06 (-8.68%)
Updated Oct 7, 2026, 7:42 AM
SID Score
6.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.02B
- P/E ratio
- 17.11
- Dividend yield
- 0.00%
- 52-week range
- $15.56 – $70.75
- Volume
- 2.57M
- Avg. volume
- 1.12M
Price performance · CDNA
CDNA price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
CDNA closed at $63.79 after 21 trading sessions, up 26.79% for the selected period.
- Last close
- $63.79
- Period change
- +26.79%
- Period low
- $50.02
- Period high
- $69.85
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $70.89 | $72.51 | $63.74 | $63.79 | 2.57M |
| Oct 5, 2026 | $66.89 | $70.75 | $66.17 | $69.85 | 1.64M |
| Oct 2, 2026 | $66.33 | $69.80 | $65.88 | $67.15 | 1.59M |
| Oct 1, 2026 | $64.955 | $67.2896 | $64.15 | $66.23 | 1.91M |
| Sep 30, 2026 | $63.87 | $65.63 | $63.115 | $65.00 | 1.77M |
| Sep 29, 2026 | $64.74 | $65.50 | $62.895 | $64.02 | 796.31K |
| Sep 28, 2026 | $62.30 | $65.495 | $62.30 | $64.60 | 1.08M |
| Sep 25, 2026 | $61.33 | $65.19 | $60.51 | $63.68 | 2.35M |
| Sep 24, 2026 | $55.29 | $63.09 | $54.52 | $61.37 | 2.5M |
| Sep 23, 2026 | $56.25 | $57.16 | $54.00 | $54.31 | 1.91M |
| Sep 22, 2026 | $54.44 | $56.85 | $53.78 | $56.49 | 1.97M |
| Sep 21, 2026 | $53.82 | $54.86 | $53.50 | $54.33 | 766.87K |
| Sep 18, 2026 | $53.97 | $54.46 | $53.12 | $53.83 | 1.38M |
| Sep 17, 2026 | $54.00 | $55.16 | $53.206 | $54.28 | 806.7K |
| Sep 16, 2026 | $52.61 | $54.488 | $52.61 | $53.55 | 846.28K |
| Sep 15, 2026 | $52.20 | $53.74 | $51.7301 | $52.64 | 950.02K |
| Sep 14, 2026 | $50.49 | $52.67 | $50.17 | $52.37 | 795.53K |
| Sep 11, 2026 | $50.14 | $50.85 | $49.57 | $50.26 | 663.05K |
| Sep 10, 2026 | $49.19 | $51.69 | $48.64 | $50.02 | 1.61M |
| Sep 9, 2026 | $49.875 | $51.33 | $49.64 | $50.03 | 1.22M |
| Sep 8, 2026 | $50.50 | $50.87 | $49.46 | $50.31 | 935.08K |
Latest CDNA news
The latest Smart Investors Daily articles mentioning CDNA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CDNA research
Overview
Company profile and research snapshot.
Company profile
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $28.80
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2026 | BTIG | Buy | — |
| Sep 2, 2026 | Canaccord Genuity | Buy | — |
| Aug 6, 2026 | BTIG | Buy | — |
| Jul 31, 2026 | HC Wainwright & Co. | Neutral | — |
| Jul 16, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 25, 2026
CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Yahoo · Sep 24, 2026
CareDx +14% on Fresh $74 Analyst Price Target
CareDx (CDNA) is up about 14% today after BTIG raised its price target from $60 to $74 and maintained its Buy rating. That’s a big move for a target bump – and there may be even more upside to be had… The detailsBTIG hosted CareDx’s CEO, CFO, and head of investor relations for investor meetings in Boston earlier this week, and came away more bullish: Target raised 23%, from $60 to $74Management sounded confident after the positive resolution of the transplant local coverage determination (this i
Benzinga · Sep 24, 2026
BTIG Maintains Buy on CareDx, Raises Price Target to $74
BTIG analyst Mark Massaro maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $60 to $74.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
